{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-163050","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.224000+00:00","generated_at":"2026-06-01T03:56:49.885438+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha Gene Therapies announces positive TSHA-102 clinical data; IDMC approves early advancement to high dose cohort","bullets":["Longer-term adult data (up to 52 weeks) show durable improvements in motor, communication, autonomic, and seizure domains.","Adult patient 1 gained ability to sit unassisted for first time in over a decade; patient 2 seizure-free for 8.5 months at 25% lower anti-seizure medication.","Initial pediatric data (up to 22 weeks) show early developmental gains: improved hand function, gait, and communication via eye-gaze device.","IDMC approved early advancement to high dose cohort in pediatric trial; dosing expected Q3 2024 after review of adult high dose safety.","TSHA-102 generally well-tolerated with no drug-related serious adverse events or dose-limiting toxicities in either trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-163050","json":"https://secwatch.observer/filing/0001193125-24-163050.json","markdown":"https://secwatch.observer/filing/0001193125-24-163050.md","text":"https://secwatch.observer/filing/0001193125-24-163050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/0001193125-24-163050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:56:49.885438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}